- Record: found
- Abstract: found
- Article: not found
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
Eve Maubec
1 ,
Peter Petrow ,
Isabelle Scheer-Senyarich ,
Pierre Duvillard ,
Ludovic Lacroix ,
Julien Gelly ,
Agnès Certain ,
Xavier Duval ,
Béatrice Crickx ,
Valérie Buffard ,
Nicole Basset-Seguin ,
Pierre Saez ,
Anne-Bénédicte Duval-Modeste ,
Henri Adamski ,
Sandrine Mansard ,
Florent Grange ,
Anne Dompmartin ,
Sandrine Faivre ,
France Mentré ,
Marie-Françoise Avril
Sep 01 2011
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin (SCCS).